Internal Medicine, Medical Oncology · Washington, DC
NPI
1639225204
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
2150 Pennsylvania Ave NW
Washington, DC, 20037
Phone (202) 741-2478
Groups this clinician bills Medicare through
Medicare paid, 2024
$115K
1,066 services
Medicare patients, 2024
287
Average age 78
Drug cost, 2024
$3.9M
708 prescriptions
Company payments, 2024
$147
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Khaled El-Shami was code 99215 (office e&m - established), 510 times for 159 patients. In total Khaled El-Shami billed 1,066 services in 12 codes, and Medicare paid $115K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 510 | 159 | $118.17 | $60K |
| 99233 Hospital E&M - Subsequent | Facility | 210 | 51 | $100.70 | $21K |
| 99214 Office E&M - Established | Facility | 205 | 125 | $71.59 | $15K |
| 99223 Hospital E&M - Initial | Facility | 70 | 55 | $146.76 | $10K |
| 99205 Office E&M - New | Facility | 47 | 47 | $151.76 | $7,133 |
By year: 2022 $94K for 875 services; 2023 $101K for 912 services; 2024 $115K for 1,066 services.
Medicare prescription drug claims, 2024
In 2024, the drug Khaled El-Shami prescribed most often to Medicare patients was Dexamethasone, with 37 prescriptions and refills. In total Khaled El-Shami wrote 708 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dexamethasone Generic | 37 | 45 | 22 | $455 |
| Venclexta Venetoclax | 34 | 37 | Under 11 | $443K |
| Acyclovir Generic | 29 | 86 | 15 | $1,005 |
| Prednisone Generic | 28 | 30 | 16 | $88.19 |
| Calquence Acalabrutinib Maleate | 28 | 28 | Under 11 | $393K |
| Pomalyst Pomalidomide | 25 | 25 | Under 11 | $550K |
| Danazol Generic | 24 | 41 | Under 11 | $7,985 |
| Hydroxyurea Generic | 23 | 67 | Under 11 | $825 |
| Jakafi Ruxolitinib Phosphate | 19 | 19 | Under 11 | $299K |
| Prochlorperazine Maleate Generic | 18 | 18 | 17 | $174 |
| Brukinsa Zanubrutinib | 16 | 16 | Under 11 | $214K |
| Ondansetron Hcl Generic | 15 | 18 | 12 | $107 |
| Allopurinol Generic | 15 | 23 | Under 11 | $111 |
| Sertraline Hcl Generic | 14 | 24 | Under 11 | $94.44 |
| Valacyclovir Valacyclovir Hcl | 14 | 25 | Under 11 | $753 |
Brand drugs: - claims; generic drugs: 477 claims; opioid claims: 22.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Khaled El-Shami $147 ($147 in general payments such as food, travel and fees) from 4 companies. The largest payer was Janssen Biotech, Inc. with $74.99.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.